Literature DB >> 21397411

Experimental primary and secondary infections of domestic dogs with Ehrlichia ewingii.

Michael J Yabsley1, Dustin S Adams, Thomas P O'Connor, Ramaswamy Chandrashekar, Susan E Little.   

Abstract

In this study, the infection dynamics of Ehrlichia ewingii, causative agent of granulocytotropic ehrlichiosis in dogs and humans, was examined in experimentally infected dogs by using a combination of physical examination, hematologic and biochemical analyses, and molecular and serologic assays. For the experimental trials, blood from an E. ewingii-infected dog was inoculated intravenously into two naïve dogs and two dogs with prior experimental exposure to E. ewingii (both were negative for E. ewingii DNA by polymerase chain reaction (PCR) assay, but seropositive from initial infection 8 and 10 months prior to challenge). A negative control dog was inoculated with blood from a negative dog. The two primary infection dogs were positive for E. ewingii DNA on DPI 4, remained consistently positive until DPI 60, and were intermittently positive until the end of the study (DPI 144). The two primary infection dogs developed antibodies reactive to E. ewingii by DPI 28 and remained seropositive for the duration of the study. Primary infected dogs had intermittent fever, thrombocytopenia, and leukopenia and some dogs were hyperphosphatemic and/or had elevated ALP levels. The two challenge dogs were positive for E. ewingii DNA on DPI 4 and 18, which was similar to the primary infection dogs, but the duration of E. ewingii DNA detection was shorter. Also, the two challenged dogs did not develop pyrexia or show any hematologic or biochemical abnormalities. E. ewingii was successfully transmitted between dogs by Amblyomma americanum, but not Rhipicephalus sanguineus. This study provides data on the infection dynamics of E. ewingii in dogs during primary and challenge infections and suggests that prior exposure may lessen clinical disease during subsequent infections.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397411     DOI: 10.1016/j.vetmic.2011.02.006

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Isolation and Short-Term Persistence of Ehrlichia ewingii in Cell Culture.

Authors:  Lindsay F Killmaster; Michael L Levin
Journal:  Vector Borne Zoonotic Dis       Date:  2016-05-26       Impact factor: 2.133

2.  Intravascular persistence of Anaplasma platys, Ehrlichia chaffeensis, and Ehrlichia ewingii DNA in the blood of a dog and two family members.

Authors:  Edward B Breitschwerdt; Barbara C Hegarty; Barbara A Qurollo; Tais B Saito; Ricardo G Maggi; Lucas S Blanton; Donald H Bouyer
Journal:  Parasit Vectors       Date:  2014-07-01       Impact factor: 3.876

3.  Persistent Ehrlichia ewingii infection in dogs after natural tick infestation.

Authors:  L A Starkey; A W Barrett; M J Beall; R Chandrashekar; B Thatcher; P Tyrrell; S E Little
Journal:  J Vet Intern Med       Date:  2015-03-16       Impact factor: 3.333

Review 4.  Blocking transmission of vector-borne diseases.

Authors:  Sandra Schorderet-Weber; Sandra Noack; Paul M Selzer; Ronald Kaminsky
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-01-30       Impact factor: 4.077

5.  Prevalence of Anaplasmataceae and Filariidae species in unowned and military dogs in New Caledonia.

Authors:  Mustapha Dahmani; Djamel Tahir; Olivier Cabre; Didier Raoult; Florence Fenollar; Bernard Davoust; Oleg Mediannikov
Journal:  Vet Med Sci       Date:  2018-03-08

Review 6.  Ehrlichioses: An Important One Health Opportunity.

Authors:  Tais B Saito; David H Walker
Journal:  Vet Sci       Date:  2016-08-31

7.  Clinicopathological findings in 41 dogs (2008-2018) naturally infected with Ehrlichia ewingii.

Authors:  Barbara A Qurollo; Jesse Buch; Ramaswamy Chandrashekar; Melissa J Beall; Edward B Breitschwerdt; Caroline B Yancey; Alexander H Caudill; Alaire Comyn
Journal:  J Vet Intern Med       Date:  2019-01-02       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.